rwj-67657 and Arthritis--Rheumatoid

To investigate the effect of the p38 mitogen activated protein kinase (MAPK) inhibitor RWJ 67657 on inflammatory mediator production by rheumatoid synovial fibroblasts (RSF).. RSF were pretreated with RWJ 67657 and stimulated with TNF alpha and/or IL-1 beta. Protein levels and mRNA expression of MMP-1, MMP-3, TIMP-1, IL-6, and IL-8 were determined, as was mRNA expression of COX-2 and ADAMTS-4.. MMP-3 production was significantly inhibited at 1 microM RWJ 67657 and MMP-1 production at 10 microM, while TIMP-1 production was not inhibited. Inhibition of IL-6 and IL-8 protein production was seen at 0.1 microM RWJ 67657. Expression profiles of mRNA were in accordance with protein production. Inhibition of COX-2 mRNA expression occurred at 0.01 microM RWJ 67657.. RWJ 67657 inhibits major proinflammatory mediator production in stimulated RSF at pharmacologically relevant concentrations. These findings could have important relevance for the treatment of rheumatoid arthritis.

Topics: ADAM Proteins; ADAMTS4 Protein; Arthritis, Rheumatoid; Cells, Cultured; Cyclooxygenase 2; Fibroblasts; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Imidazoles; Inflammation Mediators; Interleukin-1; Interleukin-6; Interleukin-8; Isoenzymes; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Membrane Proteins; Metalloendopeptidases; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Procollagen N-Endopeptidase; Prostaglandin-Endoperoxide Synthases; Protein Kinase Inhibitors; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Stimulation, Chemical; Synovial Membrane; Tissue Inhibitor of Metalloproteinase-1; Tumor Necrosis Factor-alpha